滤泡性淋巴瘤

利妥昔单抗时代转化性滤泡性淋巴瘤的治疗模式、结局和预后因素

Patterns of care, outcomes, and prognostics for transformed follicular lymphoma in the rituximab era.

一名滤泡性淋巴瘤患者从诊断到治愈的经历：CAR-T 细胞疗法带来的改变人生的影响

A patient's experience with follicular lymphoma from diagnosis to cure: the life-changing impact of CAR T-cell therapy.

axicabtagene ciloleucel 治疗复发/难治性惰性非霍奇金淋巴瘤的 ZUMA-5 研究通俗语言摘要

Plain language summary of the ZUMA-5 study of axicabtagene ciloleucel for people with relapsed or refractory slow-growing non-Hodgkin lymphoma.

滤泡性淋巴瘤与微环境：潜在靶点与生物标志物

Follicular lymphoma and the microenvironment: potential targets and biomarkers.

CD19 CAR-T 细胞疗法 (GLPG5101) 治疗复发/难治性 B 细胞非霍奇金淋巴瘤 (ATALANTA-1)：单臂、多中心 1/2 期研究的 1 期结果

CD19 CAR T-cell therapy (GLPG5101) for relapsed or refractory B-cell non-Hodgkin lymphoma (ATALANTA-1): phase 1 results from a single-arm, multicentre

本研究结果显示，在重度经治的 B 细胞非霍奇金淋巴瘤中，快速多中心分散式生产并递送新鲜 CAR-T 细胞疗法具有可行性。

CAR-T 细胞治疗后的 B 细胞缺乏：发生率、动力学、预后意义与临床管理

B Cell Aplasia Following CAR T Cell Therapy: Incidence, Kinetics, Prognostic Implications, and Clinical Management.

低分割放疗联合 PD-1 抑制剂治疗 CD19 CAR-T 治疗失败后的复发/难治性 B 细胞淋巴瘤

Hypo-fractionated radiotherapy combined with PD-1 inhibitor for relapsed/refractory B-cell lymphoma after failure to CD19 CAR-T therapy.

既往苯达莫司汀暴露对滤泡性淋巴瘤 CAR-T 细胞治疗结局的影响

Impact of Prior Bendamustine Exposure on Chimeric Antigen Receptor T-Cell Therapy Outcomes in Follicular Lymphoma.

axicabtagene ciloleucel 或 brexucabtagene autoleucel CAR-T 细胞治疗后的细胞因子释放综合征与免疫效应细胞相关神经毒性综合征：国际血液与骨髓移植研究中心数据

Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome Following Axicabtagene Ciloleucel or Brexucabtagene Autoleucel Ch

Mosunetuzumab：一种用于滤泡性淋巴瘤的双特异性 CD20 × CD3 抗体，在其他 B-NHL 亚型中具有良好前景

Mosunetuzumab: A bispecific CD20 × CD3 antibody for follicular lymphoma with promising evidence in other B-NHL subtypes.